← Back to Search

Procedure

Radiation for Pancreatic Cancer

Phase 3
Waitlist Available
Led By Ethan Ludmir, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18
Between one and five distant metastatic lesions
Must not have
Leptomeningeal disease
Peritoneal carcinomatosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion; an average of 1 year
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing whether a specific treatment can help pancreatic cancer patients with limited spread of the disease live longer without the cancer getting worse and improve overall survival.

Who is the study for?
The EXPAND trial is for individuals with a specific type of pancreatic cancer (PDAC) that has spread to a limited number of other areas in the body. Details on who can join are not fully provided, but typically participants would need to meet certain health standards and have oligometastatic disease.
What is being tested?
This study tests whether using Consolidative Radiation improves survival times for patients with PDAC and limited metastasis. It's a phase III trial, meaning it's one of the final steps before potential approval for widespread use if successful.
What are the potential side effects?
While specific side effects are not listed here, generally, Consolidative Radiation can cause fatigue, skin reactions at the treatment site, nausea, and may affect nearby organs depending on where radiation is targeted.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have between 1 and 5 cancer spread sites.
Select...
My diagnosis is stage IV pancreatic cancer.
Select...
I can perform all self-care but may not be able to do heavy physical work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My cancer has spread to the lining of my brain and spinal cord.
Select...
My cancer has spread to the lining of my abdomen.
Select...
I have an active condition like scleroderma or lupus that makes radiotherapy unsafe for me.
Select...
I have fluid buildup due to cancer spread.
Select...
I have had more than 4 treatments for cancer that has spread.
Select...
I have another cancer that significantly threatens my life.
Select...
My bone marrow is widely affected but I don't have bone metastasis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion; an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion; an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety and Adverse Events (AEs)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Group I: System Therapy (control)Experimental Treatment1 Intervention
Patients will be randomized 1:1 to (a) MDT or (b) systemic therapy alone (no MDT).
Group II: MDT (Metastasis-Directed Therapy)Experimental Treatment1 Intervention
Patients will be randomized 1:1 to (a) MDT or (b) systemic therapy alone (no MDT).

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,068 Previous Clinical Trials
1,802,599 Total Patients Enrolled
Ethan Ludmir, MDPrincipal InvestigatorM.D. Anderson Cancer Center
~53 spots leftby Jun 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top